Oxford BioTherapeutics Ltd
USPTO PatentsView assignee record - 12 granted patents across 8 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).
The verdict
According to USPTO PatentsView, Oxford ranks #23,157 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 8 technology areas.
- #23,157
- of 49,997 US assignees by volume
- 49th percentile
- by Innovation Score (34.8/100)
- 21.0
- avg claims per patent
- -80%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R23157 · Foreign Corporation #23,157 · 12 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 12 grants
- MID-PACK #23,157/49,997
- PHOTO-FINISH Orphazyme A/S
- CPC-NARROW C07K · 8 areas
- INNOV-THIN 34.8/100
- CLAIMS-DENSE 21.0 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -80% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Orphazyme A/S (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Oxford’s 34.8 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Oxford
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Oxford BioTherapeutics · this assignee
Oxford BioTherapeutics · this assignee
35 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Oxford's Innovation Score is 34.8/100 (49th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Oxford?
Each dot is one of Oxford’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oxford’s own 21.0 claims/patent is ABOVE the 14.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Oxford's grants concentrate
Oxford BioTherapeutics Ltd is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2017. By volume, Oxford sits between Orphazyme A/S and PCI Biotech AS.
Oxford's three-year grant acceleration
Oxford BioTherapeutics Ltd shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Oxford's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Orphazyme A/S
Orphazyme A/S
12 patents
- Ortho Systems
Ortho Systems
12 patents
- Orthofix US
Orthofix US LLC
12 patents
- Oscilla Power
Oscilla Power Inc.
12 patents
- Pablo AIR Interna…
Pablo AIR International, Inc.
12 patents
- Paneratech
Paneratech, Inc.
12 patents
- Pari Spezialisten…
Pari GmbH Spezialisten für effektive Inhalation
12 patents
- PCI Biotech AS
PCI Biotech AS
12 patents
- Oxford Biotherape… ◀
Oxford BioTherapeutics Ltd
12 patents
What this shows Oxford holds 12 patents at rank #23,151, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Oxford
By rank, the assignees closest to #23,151 in granted patent volume.
- Orphazyme A/S #23,147 · 12 patents
- Ortho Systems #23,148 · 12 patents
- Orthofix US LLC #23,149 · 12 patents
- Oscilla Power Inc. #23,150 · 12 patents
- Pablo AIR International, Inc. #23,152 · 12 patents
- Paneratech, Inc. #23,153 · 12 patents
- Pari GmbH Spezialisten für effektive Inhalation #23,154 · 12 patents
- PCI Biotech AS #23,155 · 12 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Oxford's primary technology class.
- The Regents of the University of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies GmbH 678 in class
- Genentech, Inc. 565 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 513 in class
- The Trustees of the University of Pennsylvania 501 in class
- Novartis AG 407 in class
- The Board of Trustees of the Leland Stanford Junior University 400 in class
Oxford's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
35 49th percentile higher than 49% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 25.0% |
| 2016 | 2 | 16.7% |
| 2017 | 1 | 8.3% |
| 2018 | 3 | 25.0% |
| 2019 | 1 | 8.3% |
| 2021 | 1 | 8.3% |
| 2023 | 1 | 8.3% |
Which technologies does Oxford BioTherapeutics Ltd patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Oxford BioTherapeutics Ltd's patent record in context - here's where to go next.
- Oxford BioTherapeutics Ltd's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
- Ranked #23,157 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Oxford BioTherapeutics Ltd against Orphazyme A/S, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 34.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.